PSORIATIC ARTHRITIS TREATMENT MARKET ANALYSIS BY TYPE, APPLICATION, REGIONS AND COMPANIES FORECAST
2024-11-27 | Pages: 200+ | Report ID: BYR-193925 | Health Care
Historical data: 2018 - 2023
Forecast period: 2024 - 2031
Quantitative units: Revenue in USD million and CAGR from 2024 to 2031
Report coverage: Revenue forecast, company ranking, competitive landscape, growth factors, and trends
Psoriatic Arthritis Treatment Market
1.1 SCOPE OF THE REPORT
1.2 MARKET SEGMENT ANALYSIS
1.3 REGULATORY SCENARIO BY REGION/COUNTRY
1.4 MARKET INVESTMENT SCENARIO STRATEGIC
1.5 MARKET ANALYSIS BY TYPE (USD MILLION)
1.6 MARKET ANALYSIS BY APPLICATION (USD MILLION)
2.1 DRIVER, RESTRAINT, CHALLENGE AND OPPORTUNITIES ANALYSIS
2.1.1 MARKET DRIVER ANALYSIS
2.1.2 MARKET RESTRAINT ANALYSIS
2.1.3 MARKET OPPORTUNITY
2.1.4 MARKET CHALLENGES
3.1 INDUSTRY TRENDS
3.1.1 SWOT ANALYSIS
3.1.2 PESTEL ANALYSIS
3.1.3 PORTER’S FIVE FORCES ANALYSIS
3.2 POTENTIAL MARKET AND GROWTH POTENTIAL ANALYSIS
4.1 COVID-19 ANALYSIS
5.1 GLOBAL PSORIATIC ARTHRITIS TREATMENT MARKET, SALES AREA, TYPE
5.2 MERGERS & ACQUISITIONS, PARTNERSHIPS, PRODUCT LAUNCH, AND COLLABORATION IN GLOBAL PSORIATIC ARTHRITIS TREATMENT MARKET
7.1 GLOBAL PSORIATIC ARTHRITIS TREATMENT MARKET SIZE AND SHARE (2018-2031) (USD MILLION)
8.1 GLOBAL PSORIATIC ARTHRITIS TREATMENT MARKET SIZE AND SHARE BY TYPE (2018-2023) (USD MILLION)
8.2 GLOBAL PSORIATIC ARTHRITIS TREATMENT MARKET SIZE AND SHARE BY TYPE (2024-2031) (USD MILLION)
9.1 GLOBAL PSORIATIC ARTHRITIS TREATMENT MARKET SIZE AND SHARE BY APPLICATION (2018-2023) (USD MILLION)
9.2 GLOBAL PSORIATIC ARTHRITIS TREATMENT MARKET SIZE AND SHARE BY APPLICATION (2024-2031) (USD MILLION)
10.1 GLOBAL PSORIATIC ARTHRITIS TREATMENT MARKET SIZE AND SHARE BY REGION (2018-2023) (USD MILLION)
10.2 GLOBAL PSORIATIC ARTHRITIS TREATMENT MARKET SIZE AND SHARE BY REGION (2024-2031) (USD MILLION)
11.1 NORTH AMERICA PSORIATIC ARTHRITIS TREATMENT MARKET SIZE AND SHARE BY COUNTRY (2018-2023) (USD MILLION)
11.2 NORTH AMERICA PSORIATIC ARTHRITIS TREATMENT MARKET SIZE AND SHARE BY COUNTRY (2024-2031) (USD MILLION)
11.3 NORTH AMERICA PSORIATIC ARTHRITIS TREATMENT MARKET SIZE AND SHARE BY TYPE (2018-2023) (USD MILLION)
11.4 NORTH AMERICA PSORIATIC ARTHRITIS TREATMENT MARKET SIZE AND SHARE BY TYPE (2024-2031) (USD MILLION)
11.5 NORTH AMERICA PSORIATIC ARTHRITIS TREATMENT MARKET SIZE AND SHARE BY APPLICATION (2018-2023) (USD MILLION)
11.6 NORTH AMERICA PSORIATIC ARTHRITIS TREATMENT MARKET SIZE AND SHARE BY APPLICATION (2024-2031) (USD MILLION)
12.1 EUROPE PSORIATIC ARTHRITIS TREATMENT MARKET SIZE AND SHARE BY COUNTRY (2018-2023) (USD MILLION)
12.2 EUROPE PSORIATIC ARTHRITIS TREATMENT MARKET SIZE AND SHARE BY COUNTRY (2024-2031) (USD MILLION)
12.3 EUROPE PSORIATIC ARTHRITIS TREATMENT MARKET SIZE AND SHARE BY TYPE (2018-2023) (USD MILLION)
12.4 EUROPE PSORIATIC ARTHRITIS TREATMENT MARKET SIZE AND SHARE BY TYPE (2024-2031) (USD MILLION)
12.5 EUROPE PSORIATIC ARTHRITIS TREATMENT MARKET SIZE AND SHARE BY APPLICATION (2018-2023) (USD MILLION)
12.6 EUROPE PSORIATIC ARTHRITIS TREATMENT MARKET SIZE AND SHARE BY APPLICATION (2024-2031) (USD MILLION)
13.1 ASIA PACIFIC PSORIATIC ARTHRITIS TREATMENT MARKET SIZE AND SHARE BY COUNTRY (2018-2023) (USD MILLION)
13.2 ASIA PACIFIC PSORIATIC ARTHRITIS TREATMENT MARKET SIZE AND SHARE BY COUNTRY (2024-2031) (USD MILLION)
13.3 ASIA PACIFIC PSORIATIC ARTHRITIS TREATMENT MARKET SIZE AND SHARE BY TYPE (2018-2023) (USD MILLION)
13.4 ASIA PACIFIC PSORIATIC ARTHRITIS TREATMENT MARKET SIZE AND SHARE BY TYPE (2024-2031) (USD MILLION)
13.5 ASIA PACIFIC PSORIATIC ARTHRITIS TREATMENT MARKET SIZE AND SHARE BY APPLICATION (2018-2023) (USD MILLION)
13.6 ASIA PACIFIC PSORIATIC ARTHRITIS TREATMENT MARKET SIZE AND SHARE BY APPLICATION (2024-2031) (USD MILLION)
14.1 LATIN AMERICA PSORIATIC ARTHRITIS TREATMENT MARKET SIZE AND SHARE BY COUNTRY (2018-2023) (USD MILLION)/p>
14.2 LATIN AMERICA PSORIATIC ARTHRITIS TREATMENT MARKET SIZE AND SHARE BY COUNTRY (2024-2031) (USD MILLION)
14.3 LATIN AMERICA PSORIATIC ARTHRITIS TREATMENT MARKET SIZE AND SHARE BY TYPE (2018-2023) (USD MILLION)
14.4 LATIN AMERICA PSORIATIC ARTHRITIS TREATMENT MARKET SIZE AND SHARE BY TYPE (2024-2031) (USD MILLION)
14.5 LATIN AMERICA PSORIATIC ARTHRITIS TREATMENT MARKET SIZE AND SHARE BY APPLICATION (2018-2023) (USD MILLION)
14.6 LATIN AMERICA PSORIATIC ARTHRITIS TREATMENT MARKET SIZE AND SHARE BY APPLICATION (2024-2031) (USD MILLION)
15.1 MIDDLE EAST & AFRICA PSORIATIC ARTHRITIS TREATMENT MARKET SIZE AND SHARE BY COUNTRY (2018-2023) (USD MILLION)
15.2 MIDDLE EAST & AFRICA PSORIATIC ARTHRITIS TREATMENT MARKET SIZE AND SHARE BY COUNTRY (2024-2031) (USD MILLION)
15.3 MIDDLE EAST & AFRICA PSORIATIC ARTHRITIS TREATMENT MARKET SIZE AND SHARE BY TYPE (2018-2023) (USD MILLION)
15.4 MIDDLE EAST & AFRICA PSORIATIC ARTHRITIS TREATMENT MARKET SIZE AND SHARE BY TYPE (2024-2031) (USD MILLION)
15.5 MIDDLE EAST & AFRICA PSORIATIC ARTHRITIS TREATMENT MARKET SIZE AND SHARE BY APPLICATION (2018-2023) (USD MILLION)
15.6 MIDDLE EAST & AFRICA PSORIATIC ARTHRITIS TREATMENT MARKET SIZE AND SHARE BY APPLICATION (2024-2031)< (USD MILLION)/p>
16.1 Novartis International AG (Switzerland)
16.1.1 COMPANY DETAILS
16.1.2 FINANCIALS (USD MILLION)
16.1.3 PRODUCT SUMMARY
16.1.4 RECENT DEVELOPMENTS
16.2 Abbvie (United States)
16.3 Eli Lilly and Company (United States)
16.4 Roche Holding AG (Switzerland)
16.5 Merck & Co. (United States)
16.6 Amgen (United States)
16.7 Bristol Myers Squibb (United States)
16.8 Celgene Corporation (United States)
16.9 Janssen Pharmaceutica (Belgium)
16.10 Bausch Health Companies Inc. (Canada)
18.1 METHODOLOGY
18.2 RESEARCH DATA SOURCE
18.2.1 SECONDARY DATA
18.2.2 KEY DATA FROM SECONDARY
18.2.3 PRIMARY DATA
18.2.4 KEY DATA FROM PRIMARY
18.2.5 INDUSTRY INSIGHT FROM PROFESSIONAL LEADERS
18.2.6 MARKET ESTIMATION
18.2.7 MARKET ESTIMATION: TOP-DOWN AND BOTTOM-UP APPROACH
18.2.8 LEGAL DISCLAIMER
Market Segments
By TreatmentMedications (NSAIDs Disease-modifying antirheumatic drugs (DMARDs) Immunosuppressants Biologic Agents and Others)
Surgical Procedures (Joint Replacement Surgery)
Steroid Injections
By Route of Administration
Oral
Parentaral
Topical
By End-users
Hospitals
Clinics
Ambulatory Surgical Centres
By Distribution Channel
Hospital Pharamacies
Retail Pharamcies
Online
Others
By Diagnosis
Imaging Tests {X-rays and Magnetic resonance imaging (MRI)}
Laboratory tests (Rheumatoid factor (RF) and Joint fluid test)
Companies
Novartis International AG (Switzerland)
Abbvie (United States)
Eli Lilly and Company (United States)
Roche Holding AG (Switzerland)
Merck & Co. (United States)
Amgen (United States)
Bristol Myers Squibb (United States)
Celgene Corporation (United States)
Janssen Pharmaceutica (Belgium)
Bausch Health Companies Inc. (Canada)
BROWSE INDUSTRY
- PROACTIVE
- QUALITY & RELIABILITY
- GLOBAL OUTREACH
- COMPETITIVE PRICING
WHY CHOOSE US
We manage our resources 24/7 to identify issues and address them before they become problems.
We are committed to providing reliable and highly accurate data with an excellent quality control system.
6 Major regions and 40+ countries level analysis accomplished.
Our pricing strategy is highly competitive in the market, without compensating on the quality and the timeline of project delivery.